ECM-Affinity Anti-Inflammatory Peptides for Inflamed Tissue Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory and autoimmune diseases often fail to effectively target inflamed tissues due to rapid clearance, leading to systemic side effects and incomplete cure, despite the potential of the enhanced permeability and retention effect in inflamed tissues.
Innovation Solution
Engineering anti-inflammatory agents with collagen-binding peptides (CBP) and vWF A3 to achieve targeted therapy by linking them to extracellular matrix (ECM)-affinity peptides, allowing for both systemic and local administration with reduced doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-inflammatory agents are administered systemically, then the therapeutic coverage is broad, but the accumulation in inflamed tissues is insufficient due to rapid clearance
Solution Approach 1:
The patent employs ECM-affinity peptides as intermediary molecules that mediate between the anti-inflammatory agent and the inflamed tissue. These peptides bind to the agent and facilitate its accumulation in inflamed tissues through interactions with extracellular matrix components, thereby resolving the contradiction between systemic administration and tissue-specific accumulation.
Solution Approach 2:
The invention imparts local quality to the anti-inflammatory agent by conjugating it with ECM-affinity peptides that have specific affinity for extracellular matrix components found in inflamed tissues. This creates a localized accumulation effect at the site of inflammation while maintaining the ability to be administered systemically.
2Quantity of substance
If anti-inflammatory agents are targeted to inflamed tissues, then the local concentration is increased, but the development of systemic side effects is reduced
Solution Approach 1:
The ECM-affinity peptide acts as a mediator that directs the anti-inflammatory agent to inflamed tissues through specific binding interactions with extracellular matrix components. This intermediary mechanism enables localized accumulation while minimizing distribution to healthy tissues, thereby reducing systemic side effects.
Solution Approach 2:
By conjugating the anti-inflammatory agent with ECM-affinity peptides, the invention creates a formulation that exhibits local quality - specifically accumulating in tissues with particular extracellular matrix characteristics (i.e., inflamed tissues) while avoiding non-target tissues, thus reducing systemic adverse effects.
3Reliability
If the dose of anti-inflammatory agent is increased to improve therapeutic outcome, then the cure rate increases, but the systemic toxicity increases
Solution Approach 1:
The ECM-affinity peptide serves as a mediator that enhances the therapeutic index by facilitating selective accumulation in inflamed tissues. This allows achieving effective local concentrations and improved cure rates at lower systemic doses, thereby reducing systemic toxicity while maintaining therapeutic effectiveness.
Solution Approach 2:
The conjugation of anti-inflammatory agents with ECM-affinity peptides creates a formulation with local quality that accumulates specifically in inflamed tissues. This enables higher local concentrations and improved cure rates without proportionally increasing systemic toxicity, as the agent is sequestered in the target tissue rather than distributing systemically.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ECM-affinity peptides enhance the accumulation of anti-inflammatory agents in inflamed tissues, reducing inflammation and disease severity in conditions like inflammatory bowel disease, multiple sclerosis, and arthritis, while minimizing systemic side effects.
Implementation Method 1
Inflammatory tissue releases a range of mediators that will induce the enhanced permeability and retention (EPR) effect. The EPR effect results from loose endothelial junctions allowing extravasation of macromolecules and nonfunctional lymphatics, resulting in prolonged retention of macromolecules within the solid tumors and inflamed tissues
Implementation Method 2
The invention generally relates to the field of medicine. More particularly, it concerns compositions and methods involving nucleotide constructs and proteins—including engineered anti-inflammatory agents for targeting inflamed tissues. The disclosure relates to the engineering of collagen-binding modification of anti-inflammatory agents using collagen-binding peptide (CBP) and vWF A3 to achieve targeted therapy for inflammatory diseases
Data Source
AI summary
The disclosure relates to the engineering of collagen-binding modification of anti-inflammatory agents using collagen-binding peptide (CBP) and vWF A3 to achieve targeted therapy for inflammatory diseases. Accordingly, embodiments of the disclosure relate to a composition comprising an anti-inflammatory agent operatively linked to an extracellular matrix (ECM)-affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to a serum protein and/or an ECM-affinity peptide. Further aspects of the disclosure relate to a method for treating an autoimmune or inflammatory condition in a subject comprising administering a composition of the disclosure to the subject.